Liminal Biosciences Inc. (LMNL) News
Filter LMNL News Items
LMNL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest LMNL News From Around the Web
Below are the latest news stories about Liminal BioSciences Inc that investors may wish to consider to help them evaluate LMNL as an investment opportunity.
Liminal BioSciences Reports Third Quarter 2021 Financial ResultsLiminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the third quarter ended September 30, 2021. |
Liminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseLiminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics BusinessLiminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that it has closed on the sale of the remainder of the Company's plasma-derived therapeutics business (the "Second Closing") under the terms of the previously-announced Share Purchase Agreement entered into by the Company and Kedrion S.p.A. ("Kedrion"). |
Liminal BioSciences Announces Closing of Sale of Priority Review VoucherLiminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that its subsidiary Prometic Biotherapeutics Inc. ("PBT") has closed on the sale of its Priority Review Voucher ("PRV") for USD 105 million. |
After Plunging 34.5% in 4 Weeks, Here's Why the Trend Might Reverse for Liminal BioSciences Inc. (LMNL)Liminal BioSciences Inc. (LMNL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayGood morning, investor! |
Liminal BioSciences Reports Second Quarter 2021 Financial ResultsLiminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today reported its financial results for the second quarter ended June 30, 2021. |
Liminal BioSciences Announces Sale of Priority Review Voucher for USD105MLiminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that, its subsidiary Prometic Biotherapeutics Inc. ("PBT") has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for USD105M. |
Liminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseLiminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Liminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing FacilityLiminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has closed on the previously announced divestment of its plasma-derived therapeutics manufacturing subsidiary to Kedrion S.p.A. ("Kedrion") (the "First Closing"). The manufacturing facility is operated through Liminal BioSciences' subsidiary, Prometic Bioproduction Inc. ("PBP"). |